CoChat

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Open access

Published version of a preprint

The DOI matches its Crossref record; 54 of the 60 references it cites were found in a registry or an index, and 4 are not checked yet; 12 of the 42 sources its claims cite were checked for support.

Abstract

Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor of GDP-bound KRASG12C that forms novel interactions with the switch II pocket. JDQ443 potently inhibits KRASG12C-driven cellular signaling and demonstrates selective antiproliferative activity in KRASG12C-mutated cell lines, including those with G12C/H95 double mutations. In vivo, JDQ443 induces AUC exposure-driven antitumor efficacy in KRASG12C-mutated cell-derived (CDX) and patient-derived (PDX) tumor xenografts. In PDX models, single-agent JDQ443 activity is enhanced by combination with inhibitors of SHP2, MEK, or CDK4/6. Notably, the benefit of JDQ443 plus the SHP2 inhibitor TNO155 is maintained at reduced doses of either agent in CDX models, consistent with mechanistic synergy. JDQ443 is in clinical development as monotherapy and in combination with TNO155, with both strategies showing antitumor activity in patients with KRASG12C-mutated tumors. Significance: JDQ443 is a structurally novel covalent KRASG12C inhibitor with a unique binding mode that demonstrates potent and selective antitumor activity in cell lines and in vivo models. In preclinical models and patients with KRASG12C-mutated malignancies, JDQ443 shows potent antitumor activity as monotherapy and in combination with the SHP2 inhibitor TNO155. See related video: https://vimeo.com/720726054 This article is highlighted in the In This Issue feature, p. 1397

Verified 2026-10-06 · 4 references not checked yet

Overview

CoChat Summary

TL;DR

JDQ443 is a structurally novel, orally bioavailable covalent inhibitor of GDP-bound KRASG12C with a distinct switch II pocket binding mode, potent mutant-selective preclinical activity, and early clinical responses alone and with the SHP2 inhibitor TNO155. Preclinical efficacy is driven by daily AUC and sustained KRASG12C target occupancy, and combinations improve single-agent activity in NSCLC and colorectal cancer models.

Key findings

  • JDQ443 covalently and selectively binds GDP-bound KRASG12C: biochemical kinact/Ki was 141 (5.1) [34], with low reversible binding affinity to RAS WT paralogs in the GDP-bound state and all GMPNP-bound affinities >200; cellular cRAF recruitment IC50 was 0.012 (0.0008) for KRASG12C versus >1 for KRASWT, NRASWT, and HRASWT (Table 1).
  • JDQ443 selectively inhibited KRASG12C-mutated cell lines in a 242-line CCLE panel (17 KRASG12C-mutant, 225 non–G12C-mutant) and showed proteome-wide selectivity by competing >2-fold with the KRAS cysteine-12 peptide among >11,500 cysteine-containing peptides, with eight additional cysteine residues on six proteins showing similar competition.
  • In CDX models, JDQ443 produced dose-dependent antitumor activity ranging from regression (MIA PaCa-2, LU99) to stasis (HCC44, NCI-H2122) to moderate inhibition (NCI-H2030, KYSE410), with no growth inhibition in a KRASG12V-mutated NCI-H441 model; efficacy correlated with daily AUC and KRASG12C target occupancy rather than Cmax or time over threshold.
  • JDQ443 plus TNO155 improved single-agent activity; in LU99 and HCC44, JDQ443 30 mg/kg q.d. plus TNO155 7.5 mg/kg b.i.d. achieved the same response as single-agent JDQ443 100 mg/kg q.d., and in KYSE410 the combination achieved tumor stasis. Two clinical cases showed RECIST 1.1 partial responses: −30.4% on JDQ443 monotherapy 200 mg b.i.d. in KRASG12C-mutated NSCLC, and −44.2% on JDQ443 200 mg q.d. plus TNO155 20 mg q.d. in KRASG12C-mutated duodenal papillary cancer.

Methods

  • Discovery used structure-based de novo design, SAR optimization, cocrystal structures, and an MS-based screen of 3,315 molecules yielding 107 confirmed hits with single KRASG12C target modification and >50% modification after 2 hours at 50 μmol/L; glutathione reactivity was used to assess promiscuous cysteine reactivity.
  • Preclinical characterization included biochemical covalent competition and surface plasmon resonance assays, NanoBiT KRAS:cRAF recruitment, pERK and proliferation assays, CCLE cell-line profiling, LC/MS tandem mass tag cysteine proteomics, Ba/F3 KRASG12C second-site mutants, CDX and PDX mouse studies, PK/PD modeling, continuous intravenous infusion, and 1 × 1 × 1 mouse clinical trial PDX panels.
  • Clinical data came from the phase Ib/II KontRASt-01 trial (NCT04699188), an open-label, multicenter dose-escalation and -expansion study of JDQ443 alone or with TNO155 and/or tislelizumab in adults with KRASG12C-mutated solid tumors; two illustrative cases are reported.

Limitations

  • The paper states that in the PDX panels, sample size did not enable conclusive correlations between genetic comutations and efficacy.
  • The paper states that phase I studies present a high risk of patient reidentification, so individual patient results cannot be shared, and some clinical data are subject to contractual or consent restrictions.
  • Evident from the text: clinical activity is illustrated by only two cases from an ongoing trial, with no mature safety, efficacy, or randomized comparison data; preclinical efficacy relies on mouse CDX/PDX models, and resistance testing covers selected KRASG12C second-site mutants rather than the full diversity of clinical resistance.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-22-0158

Cites

54 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Design of JDQ443 and its binding mode to KRASG12C. A, Scheme of the design concept to maintain the indazole and the phenyl acrylamide pharmacophores and design a scaffold to link them. Several scaffolds were evaluated in silico and the best group (dimethyl pyrazole) selected for synthesis [3] and further optimized to give JDQ443 ([5]; see Supplementary Table S1). B, Crystal structure of JDQ443 monomer 1 in complex with KRASG12C. H-bonds are shown as yellow dotted lines. The indazole moiety forms H-bond interactions with the side chain of D69 and the backbone amide donor of S65 as well as fills the hydrophobic region delimited by V103, I100, M72, and Q99 (Cα and Cβ). The pyrazole is positioned at ∼60° to the indazole fragment with the methyl pointing toward R68, T58, M72, and V9. In addition, it forms edge-to-face interactions with Y96. The spirocyclic group is a rigid linker optimally orienting the acrylamide toward C12 and the amide carbonyl to form hydrogen bond interactions with the side chain of K16 and water-mediated interaction to the Mg2+ ion and the beta phosphoryl group of GDP. The methyl–indazole moiety is almost planar to the pyrazole, and it is sandwiched between the switch II and the Q99 side chain (black dotted lines). Major differences between the two JDQ443 monomers are the conformation of H95 (pointing toward the ligand in monomer 2; Supplementary Fig. S3) and the interactions of the methyl–indazole moiety.
Figure 1. Design of JDQ443 and its binding mode to KRASG12C. A, Scheme of the design concept to maintain the indazole and the phenyl acrylamide pharmacophores and design a scaffold to link them. Several scaffolds were evaluated in silico and the best group (dimethyl pyrazole) selected for synthesis [3] and further optimized to give JDQ443 ([5]; see Supplementary Table S1). B, Crystal structure of JDQ443 monomer 1 in complex with KRASG12C. H-bonds are shown as yellow dotted lines. The indazole moiety forms H-bond interactions with the side chain of D69 and the backbone amide donor of S65 as well as fills the hydrophobic region delimited by V103, I100, M72, and Q99 (Cα and Cβ). The pyrazole is positioned at ∼60° to the indazole fragment with the methyl pointing toward R68, T58, M72, and V9. In addition, it forms edge-to-face interactions with Y96. The spirocyclic group is a rigid linker optimally orienting the acrylamide toward C12 and the amide carbonyl to form hydrogen bond interactions with the side chain of K16 and water-mediated interaction to the Mg2+ ion and the beta phosphoryl group of GDP. The methyl–indazole moiety is almost planar to the pyrazole, and it is sandwiched between the switch II and the Q99 side chain (black dotted lines). Major differences between the two JDQ443 monomers are the conformation of H95 (pointing toward the ligand in monomer 2; Supplementary Fig. S3) and the interactions of the methyl–indazole moiety.CC BY-NC-ND · PubMed Central
Figure 2. JDQ443 has selective activity for KRASG12C, including H95 double mutants, and shows dose-dependent single-dose pharmacokinetics and pharmacodynamics in mouse tumor models. A, Waterfall plot shows increased sensitivity to JDQ443 (activity area measuring the antiproliferative effect of JDQ443 relative to DMSO vehicle control over an 8-point dilution range) for 242 cancer cell line models included in this study. B, Cell lines were categorized by KRAS status (17 of 242 KRASG12C mutant); the distribution of their measured sensitivity to JDQ443 using activity area is represented in a box plot format, with the box extending from the 25th to 75th percentile with a line at the median and whiskers extending to the minimum and maximum values in each category. P value was calculated using a nonparametric unpaired t test. C, A profile of NCI-H358 cysteine reactivity with and without JDQ443 treatment (10 μmol/L, 6 hours). D, JDQ443 inhibits the proliferation of KRAS G12C/H95 double mutants. Ba/F3 cells expressing the indicated FLAG-KRASG12C single or double mutants were treated with the indicated concentrations of JDQ443 for 3 days, and the inhibition of proliferation was assessed by the CellTiter-Glo viability assay. The growth inhibition curves of one representative assay are shown. E–G, MIA PaCa-2 tumor-bearing nude mice were treated with a single oral dose of JDQ443 at indicated doses. Animals were sacrificed at multiple time points post-dose to collect blood and tumor samples to determine total drug concentrations in blood (E), LC-MS–based TO (free tumor KRASG12C; F), and tumor DUSP6 levels (G). Values are mean ± SD. conc., concentration. H, PK/PD model based on single-dose JDQ443 administration in MIA PaCa-2 xenografts predicts increased tumor KRASG12C inhibition over repeated dosing.
Figure 2. JDQ443 has selective activity for KRASG12C, including H95 double mutants, and shows dose-dependent single-dose pharmacokinetics and pharmacodynamics in mouse tumor models. A, Waterfall plot shows increased sensitivity to JDQ443 (activity area measuring the antiproliferative effect of JDQ443 relative to DMSO vehicle control over an 8-point dilution range) for 242 cancer cell line models included in this study. B, Cell lines were categorized by KRAS status (17 of 242 KRASG12C mutant); the distribution of their measured sensitivity to JDQ443 using activity area is represented in a box plot format, with the box extending from the 25th to 75th percentile with a line at the median and whiskers extending to the minimum and maximum values in each category. P value was calculated using a nonparametric unpaired t test. C, A profile of NCI-H358 cysteine reactivity with and without JDQ443 treatment (10 μmol/L, 6 hours). D, JDQ443 inhibits the proliferation of KRAS G12C/H95 double mutants. Ba/F3 cells expressing the indicated FLAG-KRASG12C single or double mutants were treated with the indicated concentrations of JDQ443 for 3 days, and the inhibition of proliferation was assessed by the CellTiter-Glo viability assay. The growth inhibition curves of one representative assay are shown. E–G, MIA PaCa-2 tumor-bearing nude mice were treated with a single oral dose of JDQ443 at indicated doses. Animals were sacrificed at multiple time points post-dose to collect blood and tumor samples to determine total drug concentrations in blood (E), LC-MS–based TO (free tumor KRASG12C; F), and tumor DUSP6 levels (G). Values are mean ± SD. conc., concentration. H, PK/PD model based on single-dose JDQ443 administration in MIA PaCa-2 xenografts predicts increased tumor KRASG12C inhibition over repeated dosing.CC BY-NC-ND · PubMed Central
Figure 3. JDQ443 displays antitumor activity across a range of cell-derived, KRASG12C-dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRASG12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRASG12C-mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRASG12C-mutated (C–G) and non–G12C-mutated (NCI-441, KRASG12V; B) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a programmable microinfusion pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood (H) and average free KRASG12C levels in tumor at steady state (I) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Figure 3. JDQ443 displays antitumor activity across a range of cell-derived, KRASG12C-dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRASG12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRASG12C-mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRASG12C-mutated (C–G) and non–G12C-mutated (NCI-441, KRASG12V; B) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a programmable microinfusion pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood (H) and average free KRASG12C levels in tumor at steady state (I) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.CC BY-NC-ND · PubMed Central
Figure 4. JDQ443 generates categorical antitumor responses in PDX models of NSCLC and colorectal tumors that are improved by combination treatment with other agents. Nude mice bearing KRASG12C-mutated NSCLC (A–D) and colorectal cancer (CRC; E–H) PDX models were treated with daily oral doses of JDQ443 at 100 mg/kg or with JDQ443 in combination with TNO155 (10 mg/kg p.o. b.i.d.), trametinib (0.3 mg/kg p.o. q.d.), or ribociclib (75 mg/kg p.o. q.d.) in a 1 × 1 × 1 format (1 mouse × 1 model × 1 treatment). Best average responses (BestAvgResp) are shown, with response categories adapted from RECIST criteria (see Methods for details). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
Figure 4. JDQ443 generates categorical antitumor responses in PDX models of NSCLC and colorectal tumors that are improved by combination treatment with other agents. Nude mice bearing KRASG12C-mutated NSCLC (A–D) and colorectal cancer (CRC; E–H) PDX models were treated with daily oral doses of JDQ443 at 100 mg/kg or with JDQ443 in combination with TNO155 (10 mg/kg p.o. b.i.d.), trametinib (0.3 mg/kg p.o. q.d.), or ribociclib (75 mg/kg p.o. q.d.) in a 1 × 1 × 1 format (1 mouse × 1 model × 1 treatment). Best average responses (BestAvgResp) are shown, with response categories adapted from RECIST criteria (see Methods for details). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.CC BY-NC-ND · PubMed Central
Figure 5. JDQ443 plus TNO155 improves the single-agent activity of JDQ443 in CDX models, with efficacy maintained with lower doses of either drug. A–F, CDX-bearing mice were treated orally (p.o.) with JDQ443, TNO155, or the combination thereof at the indicated doses and schedules. G, LU99 tumor–bearing nude mice were treated orally with JDQ443 alone or in combination with TNO155 at the indicated doses and schedules for 5 days. Tumors were taken at the indicated time points post–last dose, and free tumor KRASG12C was determined. H, LU99 tumor–bearing nude mice were treated orally with JDQ443 at the indicated doses once. Tumors were taken at 3 and 24 hours after dose, and free tumor KRASG12C was determined. Unless otherwise indicated, JDQ443 was dosed at 100 mg/kg p.o. q.d. and TNO155 at 7.5 mg/kg p.o. Data represent mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant (two-way ANOVA with Tukey multiple comparison test).
Figure 5. JDQ443 plus TNO155 improves the single-agent activity of JDQ443 in CDX models, with efficacy maintained with lower doses of either drug. A–F, CDX-bearing mice were treated orally (p.o.) with JDQ443, TNO155, or the combination thereof at the indicated doses and schedules. G, LU99 tumor–bearing nude mice were treated orally with JDQ443 alone or in combination with TNO155 at the indicated doses and schedules for 5 days. Tumors were taken at the indicated time points post–last dose, and free tumor KRASG12C was determined. H, LU99 tumor–bearing nude mice were treated orally with JDQ443 at the indicated doses once. Tumors were taken at 3 and 24 hours after dose, and free tumor KRASG12C was determined. Unless otherwise indicated, JDQ443 was dosed at 100 mg/kg p.o. q.d. and TNO155 at 7.5 mg/kg p.o. Data represent mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant (two-way ANOVA with Tukey multiple comparison test).CC BY-NC-ND · PubMed Central
Figure 6. Serial axial CT/PET images and steady-state (cycle 1, day 14) JDQ443 PK parameters for clinical cases 1 and 2. Green arrows indicate locations of tumors. PR, partial response (RECIST 1.1 by local review).
Figure 6. Serial axial CT/PET images and steady-state (cycle 1, day 14) JDQ443 PK parameters for clinical cases 1 and 2. Green arrows indicate locations of tumors. PR, partial response (RECIST 1.1 by local review).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 13 Not checked · 98 Own results and interpretations

48 more claims

Create a free account to see all 121 claims and to verify the 30 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 57

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 58 references

Research works printed but not linked: 1

  1. Weiss, KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation, Ann Oncol 2021;32(suppl_5):S1283–S1346. Abstract nr LBA6.

Cited by

See all 150

Metadata

Authors
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., Fedele, C., Gerspacher, M., Guthy, D. A., Head, V., Jaeger, A., Núñez, E. J., Kearns, J. D., Leblanc, C., Maira, S.-M., Murphy, J., Oakman, H., Ostermann, N., Ottl, J., Rigollier, P., Roman, D., Schnell, C., Sedrani, R., Shimizu, T., Stringer, R., Vaupel, A., Voshol, H., Wessels, P., Widmer, T., Wilcken, R., Xu, K., Zecri, F., Farago, A. F., Cotesta, S., & Brachmann, S. M.
Affiliations
  • Novartis (Switzerland) (CH)
  • 2Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Novartis (United States) (US)
  • 1Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • National Cancer Centre Japan (JP)
Corresponding author
  • Farago, Anna F.
  • Cotesta, Simona
Venue
Cancer Discovery
Published
2022-04-04
Volume
12
Issue
6
Pages
1500-1517
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4223470164
Cited by
150
References
60
Citations by year
2026: 24 · 2025: 33 · 2024: 46 · 2023: 43 · 2022: 4
FWCI
10.32
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
  • The Novartis Repository (Novartis) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Incyte
  • Eisai
  • Astellas Pharma
  • PharmaMar
  • SymBio Pharmaceuticals Limited
  • Genentech
  • Chugai Pharmaceutical
  • Takeda Oncology
  • Loxo Oncology
  • Daiichi Sankyo Europe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12C, covalent KRAS inhibitor, switch-II pocket, TNO155, SHP2 inhibitors, combination therapy, patient-derived xenografts, cell line-derived xenografts, anticancer activity, drug resistance, MEK inhibition, CDK4/6 inhibition
MeSH terms
Enzyme Inhibitors, Humans, Indazoles, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-0158
The paper
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., Fedele, C., Gerspacher, M., Guthy, D. A., Head, V., Jaeger, A., Núñez, E. J., Kearns, J. D., Leblanc, C., Maira, S.-M., . . . Brachmann, S. M. (2022). Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-0158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.